• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

深入研究含聚山梨酯 20 和聚山梨酯 80 的生物治疗性蛋白制剂中脂肪酸溶解度限制。

An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.

机构信息

Martin-Luther-University Halle-Wittenberg, Institute of Pharmacy, Faculty of Biosciences, Wolfgang-Langenbeck-Strasse 4, 06120 Halle (Saale), Germany.

Boehringer Ingelheim Pharma GmbH & Co. KG, Innovation Unit, PDB, Birkendorfer Straße 65, 88397 Biberach an der Riss, Germany.

出版信息

Int J Pharm. 2020 Dec 15;591:119934. doi: 10.1016/j.ijpharm.2020.119934. Epub 2020 Oct 13.

DOI:10.1016/j.ijpharm.2020.119934
PMID:33059015
Abstract

Two of the most widely used surfactants to stabilize biologicals against e.g. interfacial stress are polysorbate20 (PS20) and polysorbate 80 (PS80). In recent years, polysorbate degradation in biopharmaceutical formulations has been observed. Polysorbate (PS) is mainly composed of sorbitan and isosorbide fatty acid (FA) esters, varying in their FA composition. Especially hydrolysis, which can be induced chemically as well as enzymatically, leads to the release of FAs from PS. These FAs are poorly soluble in aqueous buffer systems due to their hydrophobic nature and therefore prone to precipitation and particle formation. Since the emergence of particles in liquid formulations has to be avoided, it is important to prevent their formation. This study evaluates the solubility limits of selected FAs, which are likely to be released during the degradation of PS20 and PS80 in the presence of defined PS concentrations. Our results show that the solubility is highly dependent on the pH, the temperature, the used PS concentration and the aliphatic chain of respective FAs. Solubility of FAs, such as palmitic and oleic acid under the conditions determined in this study, are in the range of 3-130 µg·ml (12-460 µM). Furthermore, the results allow making an estimation to which extent PS may degrade before particle formation in the drug product may be expected.

摘要

两种最广泛使用的表面活性剂,例如聚山梨酯 20(PS20)和聚山梨酯 80(PS80),用于稳定生物制剂以抵抗界面压力。近年来,在生物制药制剂中观察到聚山梨酯的降解。聚山梨酯(PS)主要由山梨糖醇和异山梨醇脂肪酸(FA)酯组成,其 FA 组成不同。特别是水解,它可以化学诱导也可以酶促诱导,导致 PS 从 PS 中释放 FA。由于这些 FA 的疏水性,它们在水性缓冲体系中溶解度较差,因此容易沉淀和形成颗粒。由于必须避免液体制剂中出现颗粒,因此防止其形成很重要。本研究评估了在存在特定 PS 浓度的情况下,PS20 和 PS80 降解时可能释放的选定 FA 的溶解度极限。我们的结果表明,溶解度高度依赖于 pH 值、温度、所用 PS 浓度和相应 FA 的脂肪链。在本研究中确定的条件下,诸如棕榈酸和油酸等 FA 的溶解度在 3-130μg·ml(12-460μM)范围内。此外,这些结果可以估计在药物产品中可能出现颗粒形成之前 PS 可能降解到何种程度。

相似文献

1
An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.深入研究含聚山梨酯 20 和聚山梨酯 80 的生物治疗性蛋白制剂中脂肪酸溶解度限制。
Int J Pharm. 2020 Dec 15;591:119934. doi: 10.1016/j.ijpharm.2020.119934. Epub 2020 Oct 13.
2
Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.提高生物制药制剂中游离脂肪酸粒子形成预测的准确性:在聚山梨酯 20 降解过程中考虑酯分布。
Mol Pharm. 2020 Nov 2;17(11):4354-4363. doi: 10.1021/acs.molpharmaceut.0c00794. Epub 2020 Oct 8.
3
Assessing the polysorbate degradation fingerprints and kinetics of lipases - how the activity of polysorbate degrading hydrolases is influenced by the assay and assay conditions.评估聚山梨酯降解指纹和脂肪酶动力学——聚山梨酯降解水解酶的活性如何受测定和测定条件的影响。
Eur J Pharm Sci. 2021 Nov 1;166:105980. doi: 10.1016/j.ejps.2021.105980. Epub 2021 Aug 20.
4
Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.聚山梨酯酯级分的特性及其对蛋白药物产品稳定性的影响。
Mol Pharm. 2020 Jul 6;17(7):2345-2353. doi: 10.1021/acs.molpharmaceut.0c00093. Epub 2020 Jun 5.
5
Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?就蛋白质稳定和颗粒形成而言,是否存在一种更优质的聚山梨酯级分?
Int J Pharm. 2023 Mar 25;635:122660. doi: 10.1016/j.ijpharm.2023.122660. Epub 2023 Feb 3.
6
A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.全油酸聚山梨酯 80 的综合评估:游离脂肪酸粒子形成、界面保护和氧化降解。
Pharm Res. 2021 Mar;38(3):531-548. doi: 10.1007/s11095-021-03021-z. Epub 2021 Mar 12.
7
Complex Micellization Behavior of the Polysorbates Tween 20 and Tween 80.聚山梨酯 20 和聚山梨酯 80 的复杂胶束化行为。
Mol Pharm. 2021 Aug 2;18(8):3147-3157. doi: 10.1021/acs.molpharmaceut.1c00406. Epub 2021 Jul 12.
8
Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.蛋白质制剂中的游离脂肪酸颗粒,第2部分:聚山梨酯原料的作用。
J Pharm Sci. 2015 Feb;104(2):447-56. doi: 10.1002/jps.24144. Epub 2014 Sep 5.
9
Fatty Acids Can Induce the Formation of Proteinaceous Particles in Monoclonal Antibody Formulations.脂肪酸可诱导单克隆抗体制剂中蛋白质颗粒的形成。
J Pharm Sci. 2022 Mar;111(3):655-662. doi: 10.1016/j.xphs.2021.10.008. Epub 2021 Oct 16.
10
All-in-one stability indicating polysorbate 20 degradation root-cause analytics via UPLC-QDa.基于 UPLC-QDa 的单一组分稳定性指示聚山梨酯 20 降解根本原因分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jan 1;1232:123955. doi: 10.1016/j.jchromb.2023.123955. Epub 2023 Dec 7.

引用本文的文献

1
Competitive adsorption of a monoclonal antibody and amphiphilic polymers to the air-water interface.单克隆抗体与两亲性聚合物在气-水界面的竞争吸附。
Eur Biophys J. 2025 May 22. doi: 10.1007/s00249-025-01752-0.
2
Micellar Solvent Accessibility of Esterified Polyoxyethylene Chains as Crucial Element of Polysorbate Oxidation: A Density Functional Theory, Molecular Dynamics Simulation and Liquid Chromatography/Mass Spectrometry Investigation.酯化聚氧乙烯链的胶束溶剂可及性作为聚山梨酯氧化的关键因素:密度泛函理论、分子动力学模拟及液相色谱/质谱研究
Mol Pharm. 2025 Mar 3;22(3):1348-1364. doi: 10.1021/acs.molpharmaceut.4c01015. Epub 2025 Feb 3.
3
Polysorbates degrading enzymes in biotherapeutics - a current status and future perspectives.
生物治疗药物中的聚山梨酯降解酶——现状与未来展望
Front Bioeng Biotechnol. 2025 Jan 10;12:1490276. doi: 10.3389/fbioe.2024.1490276. eCollection 2024.
4
Illuminating a biologics development challenge: systematic characterization of CHO cell-derived hydrolases identified in monoclonal antibody formulations.阐明生物制剂开发挑战:系统表征单抗制剂中鉴定的 CHO 细胞来源的水解酶。
MAbs. 2024 Jan-Dec;16(1):2375798. doi: 10.1080/19420862.2024.2375798. Epub 2024 Jul 10.
5
High-Throughput Fluorometric Assay For Quantifying Polysorbate In Biopharmaceutical Products Using Micelle Activated Fluorescence Probe N-Phenyl-1-Naphthylamine.基于胶束增敏荧光探针 N-苯基-1-萘胺的高通量荧光法测定生物制药产品中聚山梨酯 80 的含量
Pharm Res. 2024 Jul;41(7):1455-1473. doi: 10.1007/s11095-024-03723-0. Epub 2024 Jul 2.
6
Stress-mediated polysorbate 20 degradation and its potential impact on therapeutic proteins.应激介导的聚山梨酯 20 降解及其对治疗性蛋白的潜在影响。
Pharm Res. 2024 Jun;41(6):1217-1232. doi: 10.1007/s11095-024-03700-7. Epub 2024 May 13.
7
Oxidation of polysorbates - An underestimated degradation pathway?聚山梨酯的氧化——一种被低估的降解途径?
Int J Pharm X. 2023 Jul 27;6:100202. doi: 10.1016/j.ijpx.2023.100202. eCollection 2023 Dec 15.
8
Prediction of long-term polysorbate degradation according to short-term degradation kinetics.根据短期降解动力学预测聚山梨酯的长期降解情况。
MAbs. 2023 Jan-Dec;15(1):2232486. doi: 10.1080/19420862.2023.2232486.
9
Study of Oncolytic Virus Preservation and Formulation.溶瘤病毒保存与制剂研究
Pharmaceuticals (Basel). 2023 Jun 5;16(6):843. doi: 10.3390/ph16060843.
10
A Mechanistic Understanding of Monoclonal Antibody Interfacial Protection by Hydrolytically Degraded Polysorbate 20 and 80 under IV Bag Conditions.在 IV 袋条件下,通过水解降解的聚山梨酯 20 和 80 对单克隆抗体界面保护的机理理解。
Pharm Res. 2022 Mar;39(3):563-575. doi: 10.1007/s11095-022-03217-x. Epub 2022 Mar 11.